Arbutus to Report Second Quarter 2020 Financial Results

Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) has scheduled its Q2 2020 financial results and conference call for August 7, 2020. The press release will be issued at 7:30 a.m. ET, followed by the conference call/webcast at 8:45 a.m. ET. Live access to the call can be found on Arbutus' website, with an archived version available afterward. Arbutus focuses on developing a cure for chronic hepatitis B virus infections and treatments for coronaviruses, including COVID-19. For more details, visit www.arbutusbio.com.

WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020.  The schedule for the press release and conference call/webcast are as follows:

•	Q2 2020 Press Release:	August 7, 2020 at 7:30 a.m. ET
•	Q2 2020 Conference Call/Webcast:	August 7, 2020 at 8:45 a.m. ET
•	Domestic Dial-In Number:	(866) 393-1607
•	International Dial-In Number:	(914) 495-8556
•	Conference ID Number:	4974547

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4974547.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.  Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com

 

FAQ

When will Arbutus Biopharma announce its Q2 2020 financial results?

Arbutus Biopharma will announce its Q2 2020 financial results on August 7, 2020, at 7:30 a.m. ET.

What time is the Arbutus Biopharma conference call for Q2 2020?

The conference call for Q2 2020 will take place on August 7, 2020, at 8:45 a.m. ET.

How can I access the Arbutus Biopharma Q2 2020 conference call?

You can access the conference call through the Investors section of Arbutus' website or by dialing (866) 393-1607 for domestic and (914) 495-8556 for international calls.

Is there an archived version of the Arbutus conference call available?

Yes, an archived version of the conference call will be available on Arbutus' website after the event.

What is the purpose of Arbutus Biopharma?

Arbutus Biopharma is focused on developing a cure for chronic hepatitis B virus infection and treatments for coronaviruses, including COVID-19.